Based on current studies, patients with BCR prostate cancer with positive conventional imaging and negative PSMA PET–CT imaging can undergo biopsy or BCR management options which include clinical trial, observation, SRT, or intermittent ADT (Figure 2), however, repeat molecular imaging with a different molecular tracer could be considered in the appropriate clinical context. The gene discussed is FOLH1; the disease is prostate cancer.